Biomarin Pharmaceutical Inc at Jefferies Virtual London Healthcare Conference Transcript
Good morning and good afternoon. This is Eun Yang, one of the biotech analysts at Jefferies. Our next presenting company is BioMarin. Presenting from BioMarin is J.J. Bienaimé, Chairman and CEO; as well as Brian Mueller, CFO of the company.
So before we go into Q&As, J.J. is going to provide us an overview and opening remarks. J.J.?
So yes, thank you, Eun. We appreciate the opportunity to participate today. As you know, we recently shared our third quarter results, where we provided a number of updates. On the financial side, we tightened our GAAP net income guidance, and we improved our non-GAAP income guidance for 2020. And we slightly adjusted our total revenue guidance for the full year, mainly due to the delay in the potential approval of ROCTAVIAN. So we are optimistic that long-term data with ROCTAVIAN will ultimately lead to potential approval should the data
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
